Clinical Trials
13 trialsNCT05579366 2026-05-26
RAINFOL-01
Genmab
Phase 1/2 Recruiting
NCT03564340 2026-05-08
Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
Regeneron Pharmaceuticals
Phase 1/2 Recruiting
NCT05417594 2026-05-05
CERTIS1
AstraZeneca
Phase 1/2 Recruiting
NCT01116648 2026-05-04
Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer
National Cancer Institute (NCI)
Phase 1/2 Active not recruiting
NCT03393884 2026-05-04
OVATION 2
Imunon
Phase 1/2 Active not recruiting
NCT05739981 2026-05-04
MRD
Imunon
Phase 1/2 Recruiting
NCT01012817 2026-04-29
Veliparib and Topotecan Hydrochloride in Treating Patients With Solid Tumors, Relapsed or Refractory Ovarian Cancer, or Primary Peritoneal Cancer
National Cancer Institute (NCI)
Phase 1/2 Active not recruiting
NCT05985655 2026-04-23
ELUCIDATE
Exscientia AI Limited
Phase 1/2 Recruiting
NCT05920798 2026-04-06
FRAPPE
Mayo Clinic
Phase 1/2 Recruiting
NCT04657068 2026-03-18
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
Artios Pharma Ltd
Phase 1/2 Recruiting
NCT05198804 2026-03-18
A Study of Azenosertib (ZN-c3) and Niraparib in Subjects With Platinum-Resistant Ovarian Cancer
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
Phase 1/2 Completed
NCT07480954 2026-03-18
DUAL-OV-CAR-NK
Beijing Biotech
Phase 1/2 Recruiting
NCT07460180 2026-03-10
PROOV
The Netherlands Cancer Institute
Phase 1/2 Recruiting